Alpha Tau Medical (NASDAQ:DRTS) Hits New 1-Year High – Should You Buy?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) reached a new 52-week high during trading on Wednesday . The company traded as high as $15.20 and last traded at $14.9410, with a volume of 446149 shares traded. The stock had previously closed at $14.87.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Friday, July 17th. Benchmark restated a “buy” rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Zacks Research lowered Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Barclays lifted their price target on Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd. Finally, HC Wainwright increased their price objective on shares of Alpha Tau Medical from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.40.

Alpha Tau Medical Price Performance

The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $1.40 billion, a P/E ratio of -14.89 and a beta of 1.20. The company has a fifty day simple moving average of $13.70 and a two-hundred day simple moving average of $10.60.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). Sell-side analysts expect that Alpha Tau Medical Ltd. will post -1.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Alpha Tau Medical news, CFO Raphi Levy sold 2,871 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the completion of the sale, the chief financial officer owned 90,180 shares in the company, valued at approximately $1,352,700. The trade was a 3.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 100,371 shares of company stock worth $1,210,233. 39.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DRTS. Renaissance Technologies LLC bought a new stake in Alpha Tau Medical in the first quarter valued at about $286,000. Everhart Financial Group Inc. bought a new position in Alpha Tau Medical during the second quarter worth about $126,000. Finally, Principal Financial Group Inc. bought a new position in Alpha Tau Medical during the first quarter worth about $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based biotechnology and medical technology company developing targeted alpha radiation therapies for the treatment of solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses radium-224 sources placed into or near a tumor. As the radium decays, its short-range alpha-emitting products are intended to diffuse through the tumor and destroy cancer cells.